AERD exists in up to 20% of adult asthma patients and can be a therapeutic challenge.  Likewise, ABPA is often present in patients with difficult to treat asthma.  The available biologic options for asthma therapy have expanded the treatment options for patients with these asthma endotypes.  This forum will highlight the available data for using specific biologics in AERD or ABPA and how endotypes and patient characteristics may direct the choice of a biologic agent.

Upon completion of this activity, participants should be able to:

  • Describe the data regarding use of specific biologics in AERD and ABPA
  • Describe the patient features and endotype mechanisms that may influence the choice of biologics in these endotypes 


Moderator Introduction
Caroline Horner, MD FAAAAI
Washington University School of Medicine

Biologics in Asthma Endotypes: Focus on Aspirin-Exacerbated Respiratory Disease and Allergic Bronchopulmonary Aspergillosis
Katharine  M. Woessner, MD FAAAAI
Scripps Clinic Medical Group

Please take a moment to click the link below and give us your feedback on this session: